This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Prime Therapeutics Appoints Ellyn Hosch As Chief Information Officer

ST. PAUL, Minn., April 3, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that it has promoted Ellyn Hosch to chief information officer (CIO).

"Ellyn's industry experience, combined with her knowledge of Prime and clear vision for our future, will support the company's significant growth," said Eric Elliott, president and CEO at Prime Therapeutics.

Hosch joined Prime in 2008 as vice president of application development and support. In that role, she led insourcing of Prime's claims processing system, RxCLAIM, which was successfully completed in 2011. She has also been instrumental in shaping and implementing the strategy for improving internal IT development and support processes to ensure application stability and availability. Over the last five years, Ellyn has progressively increased her scope of responsibility and contribution to Prime.

Prior to joining Prime, Hosch held leadership roles at Diversified Pharmaceutical Services, HealthPartners and UnitedHealth Group.

She has a Masters of Business Administration from the University of St. Thomas and an undergraduate degree from the University of Minnesota.

About Prime TherapeuticsPrime Therapeutics (Prime) helps people get the medicine they need to feel better and live well. Prime offers coverage for medications to health insurers, employers, seniors on Medicare and individuals. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Headquartered in St. Paul, Minn., Prime serves nearly 20 million people. It is owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Prime has been recognized as one of the fastest-growing private companies in the nation.

For more information, visit or follow @Prime_PBM on Twitter.

SOURCE Prime Therapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs